Biomarkers for dementia: putting the focus on microglia.

The current diagnosis of Alzheimer’s disease is based on clinical and cognition testing. Investigations are attempting to define the usefulness of biomarkers in the management of patients. The criteria for establishing and validating candidate biomarkers are critical. While CSF biomolecules have been proposed, markers in the serum possibly including antibodies to microglial cells may usher in a paradigm shift in the work-up of patients suspected of dementia.